Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit frontier targets in RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. As a new member of the Revolution Medicines team, you will join other outstanding Revolutionaries in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. As an Executive Director and Head of Research Computational Biology within our Biology Function, the individual will oversee the scientific and strategic direction of systems biology research and preclinical computational biology initiatives. The individual will lead a team of computational biologists and bioinformaticians focused on acquisition, organization, and analysis of large multi-omics data sets, using both public and proprietary data sources, that will help inform treatment strategies and guide patient stratification for a growing pipeline of RAS(ON) and targeted oncology therapeutics.